Investor Presentaiton
CTS Key Business Updates (Cont'd)
Overseas Clinical Operation Business Updates (Cont'd)
As of June 30, 2023, we have established collaborations with over 100 clinical sites in the United States, covering 33 states. The size of our US clinical
operation team has more than doubled from June 30, 2022, reaching 110 employees
As of June 30, 2023, we have over 40 ongoing clinical trials in the United States, including single region clinical trials and MRCTs. The scope of
therapeutic areas covered in our ongoing trials in the United States continues to expand. Starting from oncology, we have extended to vaccines,
ophthalmology, dermatology, rare diseases, neurology, and cardiovascular etc.
Completed the acquisition of Marti Farm and integrated Marti Farm's clinical operation and pharmacovigilance teams with our existing business, which
further strengthened our ability to provide high quality clinical services in Europe to our global customers
Established a local business development team in Europe and have integrated, expanded, and improved the capacity and capability of our clinical
operation and supporting teams in Europe. Multiple services including clinical operation, clinical trial design, project management, medical
monitoring, post-market studies, pharmacovigilance and quality assurance have been integrated under a single team force to response to
customers' demands as an integrated service platform
As of June 30, 2023, we have 35 ongoing clinical trial projects (including medical device clinical trials and MRCTs) in the EMEA (Europe, Middle East,
Africa) region and our employees and operational entities cover 16 countries in the EMEA region
As of June 30, 2023, we also have 31 ongoing clinical trial projects in South East Asia and Latin America regions, including 23 MRCTs, covering
multiple therapeutic areas including oncology, vaccines, cardiovascular, endocrine, and infectious disease etc.
●Tigermed
12View entire presentation